Related Experiment Video
Updated: Mar 1, 2026

Author Spotlight: Self-Assessment Protocol for Predicting Psoriatic Arthritis in Psoriasis Patients
Published on: March 1, 2024
Delays to Care in Pediatric Lupus Patients: Data From the Childhood Arthritis and Rheumatology Research Alliance
Tamar B Rubinstein1, Wenzhu B Mowrey2, Norman T Ilowite1
1Albert Einstein College of Medicine and Children's Hospital at Montfiore, Bronx, New York.
Insights
Prompt pediatric lupus treatment is crucial. Factors like family history, income, and rheumatologist availability impact delays in care for children with lupus, affecting timely diagnosis and treatment.
Area of Science:
- Pediatric Rheumatology
- Systemic Lupus Erythematosus Research
Background:
- Prompt treatment for lupus is vital to prevent severe illness and long-term complications.
- Delayed presentation to pediatric rheumatologists is a significant barrier to early intervention in pediatric lupus cases.
Purpose of the Study:
- To investigate demographic and clinical factors associated with delayed presentation in pediatric lupus patients.
- To identify predictors of early, moderate, and severe delays in seeking pediatric rheumatology care.
Main Methods:
- Analysis of 598 pediatric lupus patients from the Childhood Arthritis and Rheumatology Research Alliance (CARRA) Legacy Registry.
- Categorization of presentation times: early (<1 month), typical (1-3 months), moderate (3-12 months), and severe (≥1 year).
- Multinomial logistic regression used to determine factors associated with presentation delays.
Main Results:
- 44% of patients presented early, 23% had moderate delays, and 9% experienced severe delays (≥1 year).
- Early presentation was linked to family history of lupus, absence of discoid rash, and higher pediatric rheumatologist density.
- Severe delays were associated with younger age, low household income (<$25,000), and family history of lupus.
Conclusions:
- Significant delays in presentation (≥1 year) affect a notable minority of pediatric lupus patients.
- Access to care and family resources are critical predictors of the time to presentation for pediatric lupus.
- Understanding these factors can inform strategies to reduce delays and improve outcomes for children with lupus.
Objective:
Prompt treatment for lupus is important to prevent morbidity. A potential barrier to early treatment of pediatric lupus is delayed presentation to a pediatric rheumatologist. To better understand factors contributing to delayed presentation among pediatric lupus patients, we examined differences in demographic and clinical characteristics of lupus patients within the Childhood Arthritis and Rheumatology Research Alliance (CARRA) Legacy Registry with regard to time between symptom onset and presentation to a pediatric rheumatologist.
Methods:
We analyzed data from 598 CARRA Legacy Registry participants for differences between those who presented early (within <1 month of symptom onset), between 1-3 months (typical presentation), with moderate delays (3-12 months), and with severe delays (≥1 year). Factors associated with early presentation, moderate delay, and severe delay were determined by multinomial logistic regression.
Results:
Forty-four percent of patients presented early, while 23% had moderate delays and 9% had severe delays. Family history of lupus, absence of discoid rash, and location in a state with a higher density of pediatric rheumatologists were associated with earlier presentation. Younger age, low household income (<$25,000 per year), and a family history of lupus were associated with severe delay.
Conclusion:
Delays to care ≥1 year exist in a notable minority of pediatric lupus patients from the CARRA Legacy Registry. In this large and diverse sample of patients, access to care and family resources played an important role in predicting time to presentation to a pediatric rheumatologist.
Related Concept Videos
Pharmacokinetics in Pediatric Patients: Drug Excretion
Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies
Genome-wide Association Studies-GWAS
GWAS does not require the identification of the target gene involved in...
Hypersensitivity Reactions: Delayed Hypersensitivity Reactions
Nephrotic Syndrome II : Assessment and Medical Management
Autoimmune Disorders
Concept and Mechanism of Autoimmune Diseases
The immune...

